Ignite Creation Date:
2025-12-24 @ 10:55 PM
Ignite Modification Date:
2026-04-23 @ 1:00 AM
Study NCT ID:
NCT02731469
Status:
COMPLETED
Last Update Posted:
2019-07-01
First Post:
2016-04-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C508420', 'term': 'continuous erythropoietin receptor activator'}, {'id': 'D000068256', 'term': 'Darbepoetin alfa'}], 'ancestors': [{'id': 'D004921', 'term': 'Erythropoietin'}, {'id': 'D003115', 'term': 'Colony-Stimulating Factors'}, {'id': 'D006023', 'term': 'Glycoproteins'}, {'id': 'D006001', 'term': 'Glycoconjugates'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'linkova@biocad.ru', 'phone': '+7 (495) 992 66 28', 'title': 'Yulia Linkova Medical Director', 'phoneExt': '930', 'organization': 'Biocad'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'from the first administration of the first dose of the drug up to the end of follow up period (28 days after the last administration of the drug)', 'eventGroups': [{'id': 'EG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 0, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 1, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 2, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 2, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 0, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 0, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 2, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 4, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 4, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 4, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 5, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'platelet count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'monocytes count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'basophils increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Platelet count increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Blood bilirubin increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'AST increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'eosinophils increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Neutrophiles decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 3}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Leucocytes decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypoglycemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'AUC (0-1176 Hours)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '206974.500', 'groupId': 'OG000', 'lowerLimit': '144988.500', 'upperLimit': '485443.500'}, {'value': '657417.000', 'groupId': 'OG001', 'lowerLimit': '598401.500', 'upperLimit': '666088.500'}, {'value': '827904.750', 'groupId': 'OG002', 'lowerLimit': '362302.000', 'upperLimit': '1179816.500'}, {'value': '1360020.000', 'groupId': 'OG003', 'lowerLimit': '424094.000', 'upperLimit': '1427990.750'}, {'value': '1314197.750', 'groupId': 'OG004', 'lowerLimit': '64430.000', 'upperLimit': '1465335.500'}, {'value': '3202606.500', 'groupId': 'OG005', 'lowerLimit': '2173496.250', 'upperLimit': '4300376.000'}, {'value': '5220198.750', 'groupId': 'OG006', 'lowerLimit': '4658082.250', 'upperLimit': '5328878.250'}, {'value': '688124.000', 'groupId': 'OG007', 'lowerLimit': '478496.000', 'upperLimit': '1252376.250'}, {'value': '94628.375', 'groupId': 'OG008', 'lowerLimit': '49807.250', 'upperLimit': '113412.500'}, {'value': '6382389.188', 'groupId': 'OG009', 'lowerLimit': '4818041.5', 'upperLimit': '6826251.75'}, {'value': '2089193.125', 'groupId': 'OG010', 'lowerLimit': '789943', 'upperLimit': '2926898'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 h post dose', 'description': 'Area under curve (AUC) "concentration - time" from 0 hours to 1176 hours and to infinity', 'unitOfMeasure': 'pg*hr/ml', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Cmax', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '585.000', 'groupId': 'OG000', 'lowerLimit': '503.000', 'upperLimit': '744.000'}, {'value': '1035.000', 'groupId': 'OG001', 'lowerLimit': '854.000', 'upperLimit': '1761.000'}, {'value': '2248.000', 'groupId': 'OG002', 'lowerLimit': '1457.000', 'upperLimit': '2566.000'}, {'value': '3634.000', 'groupId': 'OG003', 'lowerLimit': '2924.000', 'upperLimit': '4954.000'}, {'value': '3541.000', 'groupId': 'OG004', 'lowerLimit': '150.000', 'upperLimit': '4110.000'}, {'value': '12023.000', 'groupId': 'OG005', 'lowerLimit': '6863.000', 'upperLimit': '12243.000'}, {'value': '15433.000', 'groupId': 'OG006', 'lowerLimit': '13286.000', 'upperLimit': '16404.000'}, {'value': '2298.000', 'groupId': 'OG007', 'lowerLimit': '1849.000', 'upperLimit': '6867.000'}, {'value': '964.500', 'groupId': 'OG008', 'lowerLimit': '870.000', 'upperLimit': '1229.000'}, {'value': '87526.5', 'groupId': 'OG009', 'lowerLimit': '69859', 'upperLimit': '93090'}, {'value': '10588', 'groupId': 'OG010', 'lowerLimit': '3713', 'upperLimit': '11692'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose', 'description': 'Maximal concentration of drug in blood after single injection', 'unitOfMeasure': 'picogram per ml', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Tmax', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '216.000', 'groupId': 'OG000', 'lowerLimit': '96.000', 'upperLimit': '504.000'}, {'value': '168.000', 'groupId': 'OG001', 'lowerLimit': '72.000', 'upperLimit': '504.000'}, {'value': '96.000', 'groupId': 'OG002', 'lowerLimit': '8.000', 'upperLimit': '96.000'}, {'value': '72.000', 'groupId': 'OG003', 'lowerLimit': '48.000', 'upperLimit': '72.000'}, {'value': '72.000', 'groupId': 'OG004', 'lowerLimit': '48.000', 'upperLimit': '168.000'}, {'value': '120.000', 'groupId': 'OG005', 'lowerLimit': '96.000', 'upperLimit': '168.000'}, {'value': '96.000', 'groupId': 'OG006', 'lowerLimit': '72.000', 'upperLimit': '96.000'}, {'value': '48.000', 'groupId': 'OG007', 'lowerLimit': '48.000', 'upperLimit': '72.000'}, {'value': '36.000', 'groupId': 'OG008', 'lowerLimit': '8.000', 'upperLimit': '36.000'}, {'value': '0.75', 'groupId': 'OG009', 'lowerLimit': '0.5', 'upperLimit': '1'}, {'value': '84', 'groupId': 'OG010', 'lowerLimit': '72', 'upperLimit': '96'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose', 'description': 'Time from 9 hours to time of maximal concentration of drug in blood after single injection', 'unitOfMeasure': 'hours', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'T1/2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '322.094', 'groupId': 'OG000', 'lowerLimit': '322.094', 'upperLimit': '322.094'}, {'value': '377.272', 'groupId': 'OG002', 'lowerLimit': '281.082', 'upperLimit': '473.461'}, {'value': '212.231', 'groupId': 'OG003', 'lowerLimit': '212.231', 'upperLimit': '212.231'}, {'value': '416.482', 'groupId': 'OG004', 'lowerLimit': '326.648', 'upperLimit': '506.316'}, {'value': '191.477', 'groupId': 'OG005', 'lowerLimit': '145.071', 'upperLimit': '495.813'}, {'value': '181.310', 'groupId': 'OG006', 'lowerLimit': '168.649', 'upperLimit': '186.681'}, {'value': '114.855', 'groupId': 'OG007', 'lowerLimit': '105.888', 'upperLimit': '256.031'}, {'value': '79.473', 'groupId': 'OG008', 'lowerLimit': '44.619', 'upperLimit': '104.605'}, {'value': '116.125', 'groupId': 'OG009', 'lowerLimit': '70.7', 'upperLimit': '120.38'}, {'value': '182.392', 'groupId': 'OG010', 'lowerLimit': '123.71', 'upperLimit': '197.76'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose', 'description': 'Half-life of drug in blood after single injection. In the coрort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of T1 / 2 was not possible', 'unitOfMeasure': 'hours', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'the calculation of the half-life in group 0,15 mcg/kg was not carried out, due to the lack of a linear terminal phase of elimination in volunteers'}, {'type': 'SECONDARY', 'title': 'Kel', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '0.002152', 'groupId': 'OG000', 'lowerLimit': '0.002152', 'upperLimit': '0.002152'}, {'value': '0.001965', 'groupId': 'OG002', 'lowerLimit': '0.001464', 'upperLimit': '0.002466'}, {'value': '0.003266', 'groupId': 'OG003', 'lowerLimit': '0.003266', 'upperLimit': '0.003266'}, {'value': '0.001746', 'groupId': 'OG004', 'lowerLimit': '0.001369', 'upperLimit': '0.002122'}, {'value': '0.003620', 'groupId': 'OG005', 'lowerLimit': '0.001398', 'upperLimit': '0.004778'}, {'value': '0.003823', 'groupId': 'OG006', 'lowerLimit': '0.003713', 'upperLimit': '0.004110'}, {'value': '0.006057', 'groupId': 'OG007', 'lowerLimit': '0.003734', 'upperLimit': '0.006549'}, {'value': '0.009019', 'groupId': 'OG008', 'lowerLimit': '0.006697', 'upperLimit': '0.019655'}, {'value': '0.005977', 'groupId': 'OG009', 'lowerLimit': '0.003424', 'upperLimit': '0.006196'}, {'value': '0.003828', 'groupId': 'OG010', 'lowerLimit': '0.001367', 'upperLimit': '0.00415'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose', 'description': 'Elimination rate constant of drug in blood after single injection. In the cohort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of Kel was not possible', 'unitOfMeasure': 'fraction per hour', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'the calculation of the Kel in group "0,15 mcg/kg" was not carried out, due to the lack of a linear terminal phase of elimination in volunteers'}, {'type': 'SECONDARY', 'title': 'Clearance of BCD-131', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '17.393', 'groupId': 'OG000', 'lowerLimit': '8.446', 'upperLimit': '24.140'}, {'value': '16.200', 'groupId': 'OG001', 'lowerLimit': '15.313', 'upperLimit': '21.808'}, {'value': '33.337', 'groupId': 'OG002', 'lowerLimit': '24.411', 'upperLimit': '83.908'}, {'value': '54.043', 'groupId': 'OG003', 'lowerLimit': '48.530', 'upperLimit': '225.304'}, {'value': '92.812', 'groupId': 'OG004', 'lowerLimit': '91.843', 'upperLimit': '1820.580'}, {'value': '65.259', 'groupId': 'OG005', 'lowerLimit': '46.682', 'upperLimit': '88.567'}, {'value': '51.774', 'groupId': 'OG006', 'lowerLimit': '51.147', 'upperLimit': '57.320'}, {'value': '108.993', 'groupId': 'OG007', 'lowerLimit': '59.886', 'upperLimit': '156.741'}, {'value': '332.263', 'groupId': 'OG008', 'lowerLimit': '304.017', 'upperLimit': '602.322'}, {'value': '29.84', 'groupId': 'OG009', 'lowerLimit': '24.293', 'upperLimit': '30.734'}, {'value': '136.391', 'groupId': 'OG010', 'lowerLimit': '48.481', 'upperLimit': '202.399'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose', 'description': 'Clearance of BCD-131 in blood after single injection', 'unitOfMeasure': 'ml per hour', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'AUEC (0-1176 Hours) - Reticulocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '10568.04', 'groupId': 'OG000', 'lowerLimit': '10107.60', 'upperLimit': '10940.76'}, {'value': '348.000', 'groupId': 'OG001', 'lowerLimit': '144.000', 'upperLimit': '1980.000'}, {'value': '2868.000', 'groupId': 'OG002', 'lowerLimit': '2664.000', 'upperLimit': '17556.00'}, {'value': '11004.00', 'groupId': 'OG003', 'lowerLimit': '6006.000', 'upperLimit': '13416.00'}, {'value': '14481.60', 'groupId': 'OG004', 'lowerLimit': '10366.80', 'upperLimit': '15530.40'}, {'value': '25512.00', 'groupId': 'OG005', 'lowerLimit': '16476.00', 'upperLimit': '30355.20'}, {'value': '69120.00', 'groupId': 'OG006', 'lowerLimit': '46183.20', 'upperLimit': '81511.20'}, {'value': '10269.72', 'groupId': 'OG007', 'lowerLimit': '3121.200', 'upperLimit': '16310.88'}, {'value': '14223.60', 'groupId': 'OG008', 'lowerLimit': '8736.000', 'upperLimit': '21257.28'}, {'value': '21370.44', 'groupId': 'OG009', 'lowerLimit': '18081.6', 'upperLimit': '22724.88'}, {'value': '13129.2', 'groupId': 'OG010', 'lowerLimit': '4432.56', 'upperLimit': '15072'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose', 'description': 'Area under effect curve (AUEC) "absolute reticulocyte count - time" from 0 to 1176 hours post-dose after single injection of study drug', 'unitOfMeasure': 'cells (10^9) * hr/l', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'AUEC (0-1176 Hours) - Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '864.00', 'groupId': 'OG000', 'lowerLimit': '528.00', 'upperLimit': '2460.00'}, {'value': '216.00', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '1260.00'}, {'value': '1992.00', 'groupId': 'OG002', 'lowerLimit': '1152.00', 'upperLimit': '3864.00'}, {'value': '4752.00', 'groupId': 'OG003', 'lowerLimit': '2688.00', 'upperLimit': '6924.00'}, {'value': '1548.00', 'groupId': 'OG004', 'lowerLimit': '1320.00', 'upperLimit': '10128.00'}, {'value': '1392.00', 'groupId': 'OG005', 'lowerLimit': '660.00', 'upperLimit': '23460.00'}, {'value': '3516.00', 'groupId': 'OG006', 'lowerLimit': '2904.00', 'upperLimit': '4248.00'}, {'value': '3492.00', 'groupId': 'OG007', 'lowerLimit': '720.00', 'upperLimit': '6156.00'}, {'value': '3120.00', 'groupId': 'OG008', 'lowerLimit': '2112.00', 'upperLimit': '4320.00'}, {'value': '4008', 'groupId': 'OG009', 'lowerLimit': '2340', 'upperLimit': '4044'}, {'value': '4632', 'groupId': 'OG010', 'lowerLimit': '2448', 'upperLimit': '4812'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose', 'description': 'Area under effect curve (AUEC) "hemoglobin - time" from 0 to 1176 hours post-dose after single injection of study drug', 'unitOfMeasure': 'gr*hr/l', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'AC-Emax - Reticulocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '23.65', 'groupId': 'OG000', 'lowerLimit': '17.15', 'upperLimit': '31.34'}, {'value': '6.00', 'groupId': 'OG001', 'lowerLimit': '6.00', 'upperLimit': '22.00'}, {'value': '13.00', 'groupId': 'OG002', 'lowerLimit': '11.00', 'upperLimit': '34.00'}, {'value': '27.00', 'groupId': 'OG003', 'lowerLimit': '12.00', 'upperLimit': '28.00'}, {'value': '20.68', 'groupId': 'OG004', 'lowerLimit': '17.00', 'upperLimit': '26.00'}, {'value': '112.00', 'groupId': 'OG005', 'lowerLimit': '81.00', 'upperLimit': '132.00'}, {'value': '110.00', 'groupId': 'OG006', 'lowerLimit': '69.00', 'upperLimit': '171.00'}, {'value': '58.00', 'groupId': 'OG007', 'lowerLimit': '48.00', 'upperLimit': '91.42'}, {'value': '62.22', 'groupId': 'OG008', 'lowerLimit': '48.00', 'upperLimit': '153.10'}, {'value': '70.18', 'groupId': 'OG009', 'lowerLimit': '67', 'upperLimit': '72.76'}, {'value': '57.5', 'groupId': 'OG010', 'lowerLimit': '45.4', 'upperLimit': '58'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose', 'description': 'Absolute maximum of reticulocyte count (AC-Emax - reticulocytes) after single injection of study drug', 'unitOfMeasure': '10e9 reticulocytes per liter"', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'AC-Emax - Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '8.00', 'groupId': 'OG000', 'lowerLimit': '3.00', 'upperLimit': '11.00'}, {'value': '2.00', 'groupId': 'OG001', 'lowerLimit': '0.00', 'upperLimit': '22.00'}, {'value': '7.00', 'groupId': 'OG002', 'lowerLimit': '5.00', 'upperLimit': '9.00'}, {'value': '9.00', 'groupId': 'OG003', 'lowerLimit': '8.00', 'upperLimit': '15.00'}, {'value': '9.00', 'groupId': 'OG004', 'lowerLimit': '6.00', 'upperLimit': '21.00'}, {'value': '6.00', 'groupId': 'OG005', 'lowerLimit': '4.00', 'upperLimit': '26.00'}, {'value': '10.00', 'groupId': 'OG006', 'lowerLimit': '8.00', 'upperLimit': '10.00'}, {'value': '10.50', 'groupId': 'OG007', 'lowerLimit': '3.00', 'upperLimit': '12.00'}, {'value': '9.00', 'groupId': 'OG008', 'lowerLimit': '8.00', 'upperLimit': '13.00'}, {'value': '11.00', 'groupId': 'OG009', 'lowerLimit': '8.00', 'upperLimit': '13.00'}, {'value': '10.5', 'groupId': 'OG010', 'lowerLimit': '9.00', 'upperLimit': '12.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose', 'description': 'Absolute maximum of hemoglobin (AC-Emax - hemoglobin) after single injection of study drug', 'unitOfMeasure': 'gramm per liter', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Intensity of Pain After Subcutaneous Injection According to Visual Analog Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '2'}, {'value': '0', 'groupId': 'OG001', 'lowerLimit': '0', 'upperLimit': '0'}, {'value': '0', 'groupId': 'OG002', 'lowerLimit': '0', 'upperLimit': '2'}, {'value': '2', 'groupId': 'OG003', 'lowerLimit': '0', 'upperLimit': '2'}, {'value': '2', 'groupId': 'OG004', 'lowerLimit': '0', 'upperLimit': '2'}, {'value': '0', 'groupId': 'OG005', 'lowerLimit': '0', 'upperLimit': '2'}, {'value': '2', 'groupId': 'OG006', 'lowerLimit': '0', 'upperLimit': '2'}, {'value': '0', 'groupId': 'OG007', 'lowerLimit': '0', 'upperLimit': '0'}, {'value': '2', 'groupId': 'OG008', 'lowerLimit': '0', 'upperLimit': '2'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'intraoperative', 'description': 'visual analog scale Minimum value - 0, Maximum value -10, Higher scores mean worse outcome', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'In second period of study, when healthy volunteers received BCD-131 in optimal dose, visual analoge scale was not applied (by protocol)'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Adverse Events and Serious Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '4', 'groupId': 'OG007'}, {'value': '4', 'groupId': 'OG008'}, {'value': '4', 'groupId': 'OG009'}, {'value': '5', 'groupId': 'OG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)', 'description': 'Total incidence of adverse events (AE)/ serious adverse events (SAE)', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Local Reactions', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)', 'description': 'Incidence of administration site reactions', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of Participants With AE/SAE 3-4 Grade CTCAE', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '1', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)', 'description': 'Incidence of Grade 3-4 AEs and SAEs.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Early Withdrawal Due to AE', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)', 'description': 'Frequency of early withdrawals due to AEs and SAEs', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Binding Antibodies to BCD-131', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '6', 'groupId': 'OG007'}, {'value': '6', 'groupId': 'OG008'}, {'value': '6', 'groupId': 'OG009'}, {'value': '6', 'groupId': 'OG010'}]}], 'groups': [{'id': 'OG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'OG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'OG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'OG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'OG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}, {'value': '0', 'groupId': 'OG008'}, {'value': '0', 'groupId': 'OG009'}, {'value': '0', 'groupId': 'OG010'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '0, day 50 post-dose', 'description': 'Incidence of Binding antibodies to BCD-131 on Day 50 after a single injection of BCD-131', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'FG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'FG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'FG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'FG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'FG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'FG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'FG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'FG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'FG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'FG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '3'}, {'groupId': 'FG005', 'numSubjects': '3'}, {'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '6'}, {'groupId': 'FG008', 'numSubjects': '6'}, {'groupId': 'FG009', 'numSubjects': '6'}, {'groupId': 'FG010', 'numSubjects': '6'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '3'}, {'groupId': 'FG005', 'numSubjects': '3'}, {'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '6'}, {'groupId': 'FG008', 'numSubjects': '6'}, {'groupId': 'FG009', 'numSubjects': '6'}, {'groupId': 'FG010', 'numSubjects': '6'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '3', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}, {'value': '6', 'groupId': 'BG007'}, {'value': '6', 'groupId': 'BG008'}, {'value': '6', 'groupId': 'BG009'}, {'value': '6', 'groupId': 'BG010'}, {'value': '45', 'groupId': 'BG011'}]}], 'groups': [{'id': 'BG000', 'title': 'BCD-131, 0.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'BG001', 'title': 'BCD-131, 0.15 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'BG002', 'title': 'BCD-131, 0.40 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'BG003', 'title': 'BCD-131, 1.05 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'BG004', 'title': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'BG005', 'title': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'BG006', 'title': 'BCD-131, 4.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously\n\nBCD-131'}, {'id': 'BG007', 'title': 'Mircera®, 1.20 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously\n\nMircera®'}, {'id': 'BG008', 'title': 'Aranesp®, 0.45 mcg/kg Subcutaneously', 'description': 'Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously\n\nAranesp®'}, {'id': 'BG009', 'title': 'BCD-131, Optimal Dose, Intravenously', 'description': 'Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously\n\nBCD-131'}, {'id': 'BG010', 'title': 'BCD-131, Optimal Dose, Subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously\n\nBCD-131'}, {'id': 'BG011', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '24', 'groupId': 'BG000', 'lowerLimit': '21', 'upperLimit': '25'}, {'value': '26', 'groupId': 'BG001', 'lowerLimit': '22', 'upperLimit': '36'}, {'value': '30', 'groupId': 'BG002', 'lowerLimit': '23', 'upperLimit': '40'}, {'value': '32', 'groupId': 'BG003', 'lowerLimit': '23', 'upperLimit': '36'}, {'value': '26', 'groupId': 'BG004', 'lowerLimit': '26', 'upperLimit': '27'}, {'value': '25', 'groupId': 'BG005', 'lowerLimit': '22', 'upperLimit': '32'}, {'value': '25', 'groupId': 'BG006', 'lowerLimit': '22', 'upperLimit': '26'}, {'value': '28', 'groupId': 'BG007', 'lowerLimit': '22', 'upperLimit': '31'}, {'value': '28', 'groupId': 'BG008', 'lowerLimit': '25', 'upperLimit': '31'}, {'value': '24', 'groupId': 'BG009', 'lowerLimit': '23', 'upperLimit': '29'}, {'value': '25', 'groupId': 'BG010', 'lowerLimit': '25', 'upperLimit': '27'}, {'value': '26', 'groupId': 'BG011', 'lowerLimit': '23', 'upperLimit': '30'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'INTER_QUARTILE_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}]}, {'title': 'Male', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '3', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}, {'value': '6', 'groupId': 'BG007'}, {'value': '6', 'groupId': 'BG008'}, {'value': '6', 'groupId': 'BG009'}, {'value': '6', 'groupId': 'BG010'}, {'value': '45', 'groupId': 'BG011'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}]}, {'title': 'White', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '3', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}, {'value': '6', 'groupId': 'BG007'}, {'value': '6', 'groupId': 'BG008'}, {'value': '6', 'groupId': 'BG009'}, {'value': '6', 'groupId': 'BG010'}, {'value': '45', 'groupId': 'BG011'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2015-09-21', 'size': 202796, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2018-10-07T11:27', 'hasProtocol': True}, {'date': '2015-09-21', 'size': 291122, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2018-10-07T11:30', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 45}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-06-15', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-10', 'completionDateStruct': {'date': '2017-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-04-08', 'studyFirstSubmitDate': '2016-04-03', 'resultsFirstSubmitDate': '2018-10-02', 'studyFirstSubmitQcDate': '2016-04-06', 'lastUpdatePostDateStruct': {'date': '2019-07-01', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2019-04-08', 'studyFirstPostDateStruct': {'date': '2016-04-07', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2019-07-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'AUC (0-1176 Hours)', 'timeFrame': '0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 h post dose', 'description': 'Area under curve (AUC) "concentration - time" from 0 hours to 1176 hours and to infinity'}], 'secondaryOutcomes': [{'measure': 'Cmax', 'timeFrame': '0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose', 'description': 'Maximal concentration of drug in blood after single injection'}, {'measure': 'Tmax', 'timeFrame': '0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose', 'description': 'Time from 9 hours to time of maximal concentration of drug in blood after single injection'}, {'measure': 'T1/2', 'timeFrame': '0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose', 'description': 'Half-life of drug in blood after single injection. In the coрort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of T1 / 2 was not possible'}, {'measure': 'Kel', 'timeFrame': '0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose', 'description': 'Elimination rate constant of drug in blood after single injection. In the cohort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of Kel was not possible'}, {'measure': 'Clearance of BCD-131', 'timeFrame': '0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose', 'description': 'Clearance of BCD-131 in blood after single injection'}, {'measure': 'AUEC (0-1176 Hours) - Reticulocytes', 'timeFrame': '0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose', 'description': 'Area under effect curve (AUEC) "absolute reticulocyte count - time" from 0 to 1176 hours post-dose after single injection of study drug'}, {'measure': 'AUEC (0-1176 Hours) - Hemoglobin', 'timeFrame': '0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose', 'description': 'Area under effect curve (AUEC) "hemoglobin - time" from 0 to 1176 hours post-dose after single injection of study drug'}, {'measure': 'AC-Emax - Reticulocytes', 'timeFrame': '0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose', 'description': 'Absolute maximum of reticulocyte count (AC-Emax - reticulocytes) after single injection of study drug'}, {'measure': 'AC-Emax - Hemoglobin', 'timeFrame': '0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose', 'description': 'Absolute maximum of hemoglobin (AC-Emax - hemoglobin) after single injection of study drug'}, {'measure': 'Intensity of Pain After Subcutaneous Injection According to Visual Analog Scale', 'timeFrame': 'intraoperative', 'description': 'visual analog scale Minimum value - 0, Maximum value -10, Higher scores mean worse outcome'}, {'measure': 'Number of Participants With Adverse Events and Serious Adverse Events', 'timeFrame': 'from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)', 'description': 'Total incidence of adverse events (AE)/ serious adverse events (SAE)'}, {'measure': 'Number of Participants With Local Reactions', 'timeFrame': 'from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)', 'description': 'Incidence of administration site reactions'}, {'measure': 'Number of Participants With AE/SAE 3-4 Grade CTCAE', 'timeFrame': 'from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)', 'description': 'Incidence of Grade 3-4 AEs and SAEs.'}, {'measure': 'Number of Participants With Early Withdrawal Due to AE', 'timeFrame': 'from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)', 'description': 'Frequency of early withdrawals due to AEs and SAEs'}, {'measure': 'Number of Participants With Binding Antibodies to BCD-131', 'timeFrame': '0, day 50 post-dose', 'description': 'Incidence of Binding antibodies to BCD-131 on Day 50 after a single injection of BCD-131'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Reticulocyte Count']}, 'descriptionModule': {'briefSummary': 'BCD-131-1 is an Open-Label Clinical Study of the Pharmacokinetics, Pharmacodynamics, Tolerability, Safety and Immunogenicity of Single Ascending Doses of BCD-131 in Healthy Volunteers', 'detailedDescription': 'BCD-131 is novel drug product of pegylated darbepoetin alfa.\n\nClinical trial BCD-131-1 will be conducted in two stages:\n\nStage I is an open-label, non-randomized clinical study of pharmacokinetics, pharmacodynamics, tolerability, safety and immunogenicity of BCD-131 given to healthy volunteers at ascending doses (Phase 1, a traditional "3+3" design).\n\nAlso, the PK and PD parameters of the closest analogues of BCD-131 (Mircera and Aranesp) given as subcutaneous injections at therapeutic doses will be evaluated.\n\nStage II aims to further evaluate pharmacokinetics, pharmacodynamics and safety of subcutaneous and intravenous injections of BCD-131 at a dose which ensures PD effects similar to those of the closest analogues (Mircera, Aranesp) given as subcutaneous injections at therapeutic doses.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Signing of the Informed Consent Form;\n2. Male sex;\n3. Age of 18 to 45 years, inclusive;\n4. BMI within normal limits (18.5-24.9 kg/m2);\n5. Healthy patients, which is proved by their medical history, physical examination and laboratory findings:\n\n * No clinically significant abnormalities of circulatory, respiratory, nervous, hematopoietic, endocrine and digestive systems, liver and kidneys in the past medical history and at screening;\n * No history of cardiovascular disorders or thyroid disorders;\n * No history of hematologic disorders, including but not limited to any type of anemia, myelodysplastic syndrome, blood cancers, hemolytic syndrome, hemoglobinopathies, coagulopathies;\n * CBC results within normal limits, including:\n\n * Hemoglobin within 132-173 g/L;\n * Hematocrit (based on CBC results) within 39-49%;\n * Platelet count within 150-400\\*109/L;\n * Absolute reticulocyte count within 30.4-93.5 \\* 109/L;\n * Blood biochemistry and urinalysis results within normal limits;\n * Serum ferritin within 20-250 µg/L;\n * Serum endogenous erythropoietin within 4.3-29.0 MIU/mL;\n * Hemodynamic parameters within normal limits: systolic blood pressure within 100-139 mmHg; diastolic blood pressure within 60-90 mmHg; heart rate within 50-90 bpm;\n * No history of chronic infections (tuberculosis) or chronic inflammation;\n * No hepatitis B or C, HIV, or syphilis;\n * No acute infections within 4 weeks prior to inclusion in the study;\n * No psychiatric disorders and other conditions (including depression) that can interfere with the volunteer's ability to follow the study protocol;\n * Well-being (in the volunteer's opinion) within 30 days prior to inclusion in the study;\n6. No history of or current (at baseline) alcohol or drug abuse;\n7. Ability of the volunteer, in the investigator's opinion, to follow the study protocol procedures;\n8. Willingness of volunteers and their sexual partners with preserved reproductive potential to use reliable contraception within 2 weeks before inclusion in the study and up to 7 weeks after the injection of the test product. This criterion is not applicable to subjects who underwent surgical sterilization. Reliable methods of contraception include one barrier method in combination with one of the following methods: spermicides, intrauterine device/oral contraceptives (for sexual partners).\n9. Willingness of volunteers to avoid alcohol intake within 24 hours before and 8 days after each injection of the test drug;\n\nExclusion Criteria:\n\n1. History of treatment with erythropoietins or any other ESAs;\n2. Acute bleeding, blood/plasma donation or blood transfusion within 2 months before inclusion in the study;\n3. History of chronic bleeding;\n4. Standard laboratory and instrumental findings outside normal limits at screening;\n5. History of allergies (anaphylactic shock or multiple drug allergy syndrome);\n6. Known allergy or intolerance to any components of the investigational product;\n7. Major surgery within 30 days prior to screening, or surgery being scheduled for any time during the study;\n8. Impossibility to install a venous catheter for blood sampling (e.g. because of skin disorders at the sites of venipuncture);\n9. Diseases or other conditions that can interfere with the pharmacokinetics of the investigational drug (e.g. chronic liver, kidney, blood, circulatory system, lung or neuroendocrine diseases, including diabetes mellitus and others);\n10. History of fever of 40 °C or more;\n11. History of elevated hepatic transaminases (above 2.5xULN);\n12. Episodes of thrombosis and/or thromboembolia in past medical history (myocardial infarction, stroke, transient ischemic attacks, deep vein thrombosis, pulmonary embolism within 6 months prior to inclusion in the study) as well as an increased risk of deep vein thrombosis;\n13. History of epileptic attacks or seizures;\n14. History or current (at screening) depression, suicidal thoughts/ attempts;\n15. Regular oral or parenteral use of any medications including over-the-counter drugs, vitamins and nutritional additives within 2 weeks before a scheduled injection of the test drug;\n16. Use of drugs, including OTC products, that significantly affect the hemodynamics, hepatic function, etc. (barbiturates, omeprazole, cimetidine, etc.) within 30 days before a scheduled injection of the test drug;\n17. Vaccination within 4 weeks before a scheduled injection of the test drug;\n18. Smoking more than 10 cigarettes per day;\n19. Consumption of more than 10 portions of alcohol per week (one portion equals to 0.5 L of beer, 200 mL of wine or 50 mL of ethanol) or a history of alcohol, drug or medication abuse;\n20. Participation in other clinical studies within 1 month before screening or simultaneous participation in another clinical study;\n21. Previous participation in this study."}, 'identificationModule': {'nctId': 'NCT02731469', 'briefTitle': 'Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers', 'organization': {'class': 'INDUSTRY', 'fullName': 'Biocad'}, 'officialTitle': 'Clinical Study of the Pharmacokinetics, Pharmacodynamics, Tolerability, Safety and Immunogenicity of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers', 'orgStudyIdInfo': {'id': 'BCD-131-1'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'BCD-131, 0.05 mcg/kg subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously', 'interventionNames': ['Biological: BCD-131']}, {'type': 'EXPERIMENTAL', 'label': 'BCD-131, 0.15 mcg/kg subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously', 'interventionNames': ['Biological: BCD-131']}, {'type': 'EXPERIMENTAL', 'label': 'BCD-131, 0.40 mcg/kg subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously', 'interventionNames': ['Biological: BCD-131']}, {'type': 'EXPERIMENTAL', 'label': 'BCD-131, 1.05 mcg/kg subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously', 'interventionNames': ['Biological: BCD-131']}, {'type': 'EXPERIMENTAL', 'label': 'BCD-131, 1.70 mcg/kg SC', 'description': 'Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously', 'interventionNames': ['Biological: BCD-131']}, {'type': 'EXPERIMENTAL', 'label': 'BCD-131, 2.25 mcg/kg SC', 'description': 'Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously', 'interventionNames': ['Biological: BCD-131']}, {'type': 'EXPERIMENTAL', 'label': 'BCD-131, 4.45 mcg/kg subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously', 'interventionNames': ['Biological: BCD-131']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Mircera®, 1.20 mcg/kg subcutaneously', 'description': 'Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously', 'interventionNames': ['Biological: Mircera®']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Aranesp®, 0.45 mcg/kg subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously', 'interventionNames': ['Biological: Aranesp®']}, {'type': 'EXPERIMENTAL', 'label': 'BCD-131, optimal dose, intravenously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously', 'interventionNames': ['Biological: BCD-131']}, {'type': 'EXPERIMENTAL', 'label': 'BCD-131, optimal dose, subcutaneously', 'description': 'Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously', 'interventionNames': ['Biological: BCD-131']}], 'interventions': [{'name': 'BCD-131', 'type': 'BIOLOGICAL', 'otherNames': ['pegylated darbepoetin alfa'], 'armGroupLabels': ['BCD-131, 0.05 mcg/kg subcutaneously', 'BCD-131, 0.15 mcg/kg subcutaneously', 'BCD-131, 0.40 mcg/kg subcutaneously', 'BCD-131, 1.05 mcg/kg subcutaneously', 'BCD-131, 1.70 mcg/kg SC', 'BCD-131, 2.25 mcg/kg SC', 'BCD-131, 4.45 mcg/kg subcutaneously', 'BCD-131, optimal dose, intravenously', 'BCD-131, optimal dose, subcutaneously']}, {'name': 'Mircera®', 'type': 'BIOLOGICAL', 'otherNames': ['Methoxy polyethylene glycol-epoetin beta'], 'armGroupLabels': ['Mircera®, 1.20 mcg/kg subcutaneously']}, {'name': 'Aranesp®', 'type': 'BIOLOGICAL', 'otherNames': ['darbepoetin alfa'], 'armGroupLabels': ['Aranesp®, 0.45 mcg/kg subcutaneously']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Roman Ivanov, PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'JCS BIOCAD'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Biocad', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}